Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide

NCT02120638 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Multidrug Resistant Tuberculosis

Interventions

DRUG: Pyrazinamide containing regimen
DRUG: Regimen without Pyrazinamide

Sponsor

Huashan Hospital